South San Francisco-based Portola Pharmaceuticals ($PTLA) has nabbed boasting rights to the FDA’s new breakthrough drug designation for andexanet alfa (PRT4445), its Factor Xa inhibitor antidote designed to hit the brake on blood thinners when they turn dangerous. And the biotech says that the BTD helps set the stage for its campaign to win an […]
↧
